News|Articles|September 12, 2025
NeurologyLive® Friday 5 — September 12, 2025
Author(s)Isabella Ciccone, MPH
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 12, 2025.
Advertisement
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: FDA Action Update, August 2025: Approvals and Complete Response Letter
Catch up on any of the neurology news headlines you may have missed over the course of August 2025, compiled all into 1 place by the NeurologyLive® team.
2: Improving Brain Health Through Lifestyle Changes in Older Adults at Risk for Dementia: Rebecca M. Edelmayer, PhD
The vice president of scientific engagement at the Alzheimer's Association shared data presented at AAIC 2025 from the phase 3 U.S. POINTER study among patients at risk for dementia. [WATCH TIME: 4 minutes]
3: 2025 LGS Meeting Reflections and Engagement Opportunities in Research
In this latest roundtable episode, experts noted that the Lennox-Gastaut syndrome Foundation is a welcoming platform for collaboration, research advancement, and career development in the field. [WATCH TIME: 3 minutes]
4: NeuroVoices: Marcus Yountz, on the Promise and Phase 2 Data of Orexin Agent Alixorexton
In our latest NeuroVoices Q&A, Marcus Yountz, VP of clinical development at Alkermes detailed phase 2 results for alixorexton, an oral, selective orexin 2 receptor agonist, in narcolepsy type 1, including benefits for fatigue, cognition, and weakness.
5: Eligibility and Safety Considerations for Antiamyloid Alzheimer Therapies
In this latest Special Report episode, Sharon Cohen, MD, FRCPC, talked about key differences between lecanemab and donanemab in terms of eligibility requirements to the receive the treatment. Supported by Eli Lilly.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Enhancing Gene Therapy Safety for Duchenne Through New Recommendations: Barry Byrne, MD, PhD
2
Expanding the Alzheimer Drug Development Pipeline
3
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
4
Patient-Reported Study Identifies Common Symptoms and Timing During Migraine Prodrome
5